research use only
Cat.No.S6659
| Related Targets | CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas |
|---|---|
| Other CGRP Receptor Inhibitors | Atogepant Vazegepant hydrochloride Ubrogepant Olcegepant Rat CGRP-(8-37) |
|
In vitro |
DMSO
: 100 mg/mL
(187.06 mM)
Ethanol : 3 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 534.56 | Formula | C28H28F2N6O3 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1289023-67-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | BHV-3000 | Smiles | C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6 | ||
| Targets/IC50/Ki |
CGRP receptor
(Cell-free assay) 0.027 nM(Ki)
|
|---|---|
| In vitro |
Rimegepant (BMS-927711, BHV-3000) is a potent, selective, competitive human calcitonin gene-related peptide (CGRP) receptor antagonist with ki of 0.027 nM. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06409832 | Recruiting | Migraine|Migraine With Aura|Migraine Without Aura|Chronic Migraine |
University of Florence|IRCCS National Neurological Institute C. Mondino Foundation|Società italiana per lo studio delle Cefalee (SISC)|Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari|Università degli Studi dell''Aquila|University of Roma La Sapienza|Azienda Ospedaliero Universitaria Policlinico Modena|Ospedale di Piove di Sacco|Azienda Ospedaliero-Universitaria di Parma|Azienda Ospedaliera S. Maria della Misericordia|Azienda Ospedaliera Città della Salute e della Scienza di Torino|Cliniche Humanitas Gavazzeni|University of Campania Luigi Vanvitelli|Ospedale di Prato|Azienda Policlinico Umberto I|Auxologico San Luca Milano|ASST Spedali Civili Brescia|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta |
March 26 2024 | -- |
| NCT05888766 | Not yet recruiting | Migraine Disorders |
University of Roma La Sapienza |
July 1 2023 | -- |
| NCT05518123 | Recruiting | Migraine |
Pfizer |
November 7 2022 | Phase 4 |
| NCT05509400 | Recruiting | Migraine |
Pfizer |
October 18 2022 | Phase 4 |
| NCT05399485 | Active not recruiting | Migraine |
Pfizer |
August 9 2022 | Phase 3 |
| NCT05262517 | Terminated | Temporomandibular Disorders (TMD) |
Pfizer |
May 5 2022 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.